Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV)22 residues (approx.)GEPPPGKPADDAGLVLKKTETQEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.Also known as: KLOW Protocol, KLOW Stack, KLOW Peptide Blend
Four research peptides in a single 80mg vial, each targeting a different repair pathway. The KLOW Blend combines GHK-Cu, BPC-157, TB-500, and KPV into a fixed-ratio formulation designed for tissue recovery, gut support, and skin integrity during aggressive fat loss. Zero clinical trials exist for the combination itself; all four components remain preclinical for injectable use in humans. That said, the individual ingredient data is real. GHK-Cu modulates over 4,000 human genes tied to collagen synthesis. BPC-157 has over 100 published preclinical studies on tissue repair. Users pair KLOW with GLP-1 agonists to offset GI side effects and preserve skin elasticity during rapid weight loss.
Does stacking four preclinical peptides in one vial actually make sense? The KLOW Blend (also called the KLOW Protocol) puts GHK-Cu (50mg), BPC-157 (10mg), TB-500 (10mg), and KPV (10mg) together in a fixed 5:1:1:1 ratio. It evolved from the three-peptide GLOW stack. The addition of KPV brought anti-inflammatory gut protection into the mix. Each component works through a separate mechanism. GHK-Cu is a copper-binding tripeptide first isolated by Loren Pickart in 1973. His gene expression studies [1] confirmed it modulates over 4,000 genes involved in collagen, elastin, and antioxidant enzyme production. BPC-157 is a 15-amino-acid gastric juice fragment. Predrag Sikiric's group in Zagreb has published over 100 preclinical papers showing it accelerates tendon outgrowth through FAK-paxillin signaling and protects gut mucosa [2]. TB-500, a synthetic fragment of thymosin beta-4, promotes actin polymerization and cell migration. Goldstein's original work showed it increased keratinocyte migration 2- to 3-fold at concentrations as low as 10pg [3]. KPV enters intestinal epithelial cells via the PepT1 transporter and suppresses NF-kB inflammatory signaling at nanomolar concentrations (Dalmasso et al.)[4]. The typical community protocol runs 2000mcg total blend per day for 10 weeks, followed by 4 weeks off. Most of the interest comes from the GLP-1 companion use case. Users on semaglutide or tirzepatide report that KLOW reduces nausea and supports skin tightening during rapid weight loss. That framing is entirely anecdotal. No clinical endpoint data supports it. The FDA classified BPC-157 and GHK-Cu as Category 2 bulk drug substances in 2023-2024, restricting compounding pharmacy access. Both BPC-157 and TB-500 are WADA-prohibited. Research vendor pricing ranges from $65 to $170 per vial.
The four peptides in KLOW operate through distinct signaling cascades that happen to converge on tissue repair, inflammation control, and extracellular matrix remodeling. GHK-Cu delivers bioavailable copper into dermal and connective tissue. It activates fibroblast proliferation and upregulates genes for collagen I, collagen III, elastin, and glycosaminoglycans. Pickart's work [1] identified over 4,000 modulated human genes, including antioxidant enzymes like superoxide dismutase. The copper chelation is not optional; free GHK tripeptide without the Cu2+ complex lacks most biological activity. BPC-157 interacts with the nitric oxide system and upregulates growth hormone receptor expression. Sikiric's research shows it promotes angiogenesis through VEGF pathway activation and accelerates tendon outgrowth via FAK-paxillin signaling [5]. It also protects endothelial function and modulates dopamine and serotonin systems. TB-500 sequesters G-actin monomers, preventing premature polymerization. This allows orderly cytoskeletal reorganization at wound sites. Goldstein's group showed thymosin beta-4 increased keratinocyte migration 2- to 3-fold at 10pg concentrations [3]. A first-in-human Phase I study of recombinant thymosin beta-4 in 48 healthy Chinese volunteers [6] established basic tolerability. KPV enters cells via the PepT1 transporter expressed on intestinal epithelial and immune cells. Once inside, it stabilizes IkB-alpha, preventing NF-kB nuclear translocation. Dalmasso et al. [4] showed oral KPV reduced colitis incidence in DSS and TNBS animal models. A separate group confirmed KPV's anti-inflammatory activity in human bronchial epithelial cells [7].
No clinical data exists for the four-peptide KLOW combination. Individual component evidence is preclinical (BPC-157, TB-500, GHK-Cu, KPV each have animal model data). First human BPC-157 IV safety pilot (Lee & Burgess 2025, n=2)[9] showed tolerability up to 20mg IV; no efficacy claims possible from n=2.
PMC12313605 (Vasireddi et al. 2025, systematic review BPC-157 orthopaedics, 35 preclinical + 1 clinical); PMID 40131143 (Lee & Burgess 2025, BPC-157 IV human pilot, n=2)
Zero combination studies. All four components are preclinical-only for injection use in humans. FDA listed BPC-157 and GHK-Cu as Category 2 bulk drug substances (compounding ban, 2023-2024). TB-500 daily micro-dose format has no precedent: standard protocol is 2×/week bolus 2–5mg.
Emerging community stack with anecdotal reports of improved skin elasticity, reduced GI symptoms on GLP-1 agonists, and faster soft-tissue recovery. Dosing is inconsistent across sources: community consensus (200–500mcg/day total blend per peptide-db.com) diverges significantly from vendor-recommended tiers (2000–6000mcg/day).
Individual components (BPC-157, GHK-Cu, KPV, TB-500) each have preclinical rationale supporting their combined use for tissue repair and inflammation. However, no combination study exists, the community-adopted GLP-1 companion framing lacks clinical evidence, and the vendor dose tiers (2000–6000mcg/day) conflict with lower community estimates (200–500mcg/day). TB-500 daily micro-dosing is structurally inconsistent with its established 2×/week bolus protocol.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 2mg | Daily |
| Moderate | 4mg | Daily |
| Aggressive | 6mg | Daily |
Reconstitution math for the 80mg vial: add 3mL bacteriostatic water to get 26.7mg/mL. At that concentration, 7.5 units on a 100-unit insulin syringe delivers 2000mcg (the beginner dose). Going with 4mL instead gives you 20mg/mL with slightly larger but easier-to-measure draw volumes. Swirl the vial gently after adding bac water. Don't shake it. Peptides aren't cocktails. The blend ratio is fixed at 5:1:1:1 (GHK-Cu : BPC-157 : TB-500 : KPV). At beginner dose (2000mcg/day) you're getting GHK-Cu 1250mcg, BPC-157 250mcg, TB-500 250mcg, and KPV 250mcg. That BPC-157 number is within its typical standalone range. The TB-500 number (250mcg daily, or ~1.75mg per week) is structurally different from the standard TB-500 protocol (2 to 5mg bolus twice per week). Whether daily low-dose TB-500 equals bolus dosing is unknown. One vial at beginner dose lasts about 40 days. At moderate (4000mcg/day) you'll burn through it in roughly 20 days. Plan your vendor orders around that. Pin once daily, preferably in the evening. Rotate between at least four injection sites (left/right abdomen, left/right outer thigh).
Run daily injections for 8-12 weeks. Weeks 1-4 serve as a loading phase at the beginner dose. Increase to moderate dosing by week 3-4 if well tolerated. Take 4 weeks off before repeating. Most users run 2-3 cycles per year. When pairing with GLP-1 agonists, start KLOW 1-2 weeks before the GLP-1 to establish a baseline of gut and tissue support.
KLOW cycling is driven primarily by safety monitoring (unstudied four-component combination; copper accumulation risk from GHK-Cu with extended use) and extrapolation from individual component protocols (BPC-157 and TB-500 are typically run in 8–12 week cycles with breaks). No receptor desensitization data exists for this combination, and no hormonal axis is suppressed.
Or use the universal Peptide Calculator for any peptide.
Expected: Reduced joint discomfort and soft tissue soreness by weeks 3–4; skin hydration and elasticity improvement by weeks 5–7; peak healing support by weeks 8–10
Monitor: Baseline copper levels recommended before starting. Monitor for skin flushing (GHK-Cu copper load). Track injection site reactions.
Wipe the rubber stopper with an alcohol swab.
Inject it slowly down the inside wall of the vial. Do not spray directly onto the peptide cake.
Do not shake. The solution should be clear with no visible particles.
Using a 29 to 31 gauge insulin syringe (100-unit markings), draw to the 7.5-unit line for a 2000mcg beginner dose. For moderate dosing (4000mcg), draw to 15 units. For aggressive (6000mcg), draw to 22.5 units.
Pinch a fold of skin on the abdomen (2 inches from the navel) or outer thigh. Insert the needle at a 45-degree angle.
Hold for 5 seconds before withdrawing the needle. Apply light pressure with an alcohol swab if needed.
Administer once daily, preferably in the evening to align with overnight tissue repair cycles. Rotate injection sites each day. Keep a brief log so you don't hit the same spot twice in a row.
Store the reconstituted vial upright in the refrigerator at 2 to 8 degrees Celsius. Use within 4 weeks of reconstitution.
Most discussed KLOW pairing. KPV targets GLP-1-induced gut inflammation; BPC-157 supports mucosal healing; GHK-Cu addresses skin elasticity during rapid weight loss.
Start KLOW 1–2 weeks before semaglutide initiation. Inject separately, different sites.
Same rationale as semaglutide. Dual GIP/GLP-1 agonism may cause more GI distress: KPV anti-inflammatory component potentially more relevant.
Post-surgical or severe injury recovery: additional standalone BPC-157 bolus to supplement the fixed-ratio KLOW blend component (which delivers only 250–750mcg/day BPC-157). Allows therapeutic BPC-157 dose without replacing the full blend.
Predecessor stack: KLOW is GLOW + KPV. Users switch from GLOW to KLOW when GI inflammation or gut support is a priority. Not typically run simultaneously.
GHK-Cu delivers bioavailable copper. Combined use risks copper overload, particularly at moderate/aggressive KLOW tiers (GHK-Cu 2500–3750mcg/day).
Do not combineCompetitive inhibition at copper transport sites reduces GHK-Cu uptake and effectiveness.
BPC-157 and GHK-Cu both promote angiogenesis; combined use may affect clotting dynamics.
KPV and TB-500 modulate immune pathways; may reduce or unpredictably amplify immunosuppressive effects.
Pricing updated 2026-04-09
Three of the four KLOW components promote angiogenesis and growth factor signaling. Anyone with a current cancer diagnosis or cancer history should not use this blend. That is the most serious safety concern, and it is not negotiable. No human clinical trial data exists for the four-peptide combination. Every side effect profile below is extrapolated from research on individual components. Injection site reactions are the most frequently reported issue. Redness, mild swelling, or itching at the injection site typically resolves within an hour. This is common across all subcutaneous peptide injections and not specific to KLOW. GHK-Cu's copper content can cause transient skin flushing. Some users describe a warm, reddish tint across the face or chest lasting 20 to 40 minutes after injection. At higher dose tiers (moderate delivers 2500mcg GHK-Cu per day; aggressive delivers 3750mcg), copper accumulation over a 10-week cycle becomes a legitimate concern. Serum copper and ceruloplasmin monitoring is recommended at baseline and mid-cycle for anyone running above the beginner tier. BPC-157 may cause mild nausea, dizziness, or headache. These effects are more common at higher doses and when injecting on an empty stomach. The first-in-human IV safety pilot by Lee and Burgess (n=2)[9] showed tolerability up to 20mg IV. That sample size tells you almost nothing about population-level side effects. TB-500 has been associated with temporary lethargy and mild headache during loading phases. Community reports suggest this fades by week 2 to 3. KPV side effects are rare in published literature. Some users experience increased fatigue during the first week. A smaller number report mild GI discomfort, bloating, or changes in bowel frequency. When paired with a GLP-1 agonist, additive GI effects in the first two weeks of overlap deserve attention. Pregnancy and breastfeeding are absolute contraindications. Wilson's disease or copper metabolism disorders rule out KLOW due to the GHK-Cu component. Active autoimmune conditions in flare warrant caution because TB-500 and BPC-157 modulate immune signaling in unpredictable ways. Long-term safety of this four-peptide combination is unknown. Stop the cycle and consult a physician if you experience persistent copper-related symptoms (metallic taste, facial flushing that does not resolve), unusual bleeding or bruising, or any signs of allergic reaction.
Verify KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV) dosing and safety with a second opinion
Multi-component research blend with no FDA oversight. BPC-157 and GHK-Cu are classified as FDA Category 2 bulk drug substances (compounding ban, 2023–2024). Wide market price range ($65–$380/vial) reflects inconsistent quality standards. No combination stability data published: peptide degradation rates within a four-component lyophilized blend are unknown. WADA prohibits BPC-157 and TB-500 (risk for tested athletes).
| Test | When | Target |
|---|---|---|
| Serum copper and ceruloplasmin | Baseline before starting; mid-cycle at week 5 if running moderate/aggressive tiers | Serum copper 70–140 mcg/dL; ceruloplasmin 20–35 mg/dL |
| Liver function panel (ALT, AST, ALP, bilirubin) | Baseline; at 6 weeks if any GI symptoms develop | Within institutional reference range |
| CBC with differential | Baseline; repeat if unusual bleeding, bruising, or infection signs occur | — |
| Cancer screening (age-appropriate, per clinical guidelines) | Before initiating any cycle; confirm no active malignancy or recent history | — |
GHK-Cu delivers bioavailable copper; at moderate tier (2500mcg GHK-Cu/day) or aggressive tier (3750mcg/day) copper accumulation is a risk over 10 weeks
No combination hepatotoxicity data exists; general safety monitoring for unstudied four-component blend
Triple pro-angiogenic combination (BPC-157 + TB-500 + GHK-Cu): monitor hematologic impact; BPC-157 interacts with clotting dynamics
Three of four components promote angiogenesis and growth factor signaling: absolute contraindication in active or historical cancer diagnosis
Subtle improvements in energy and recovery. Some users notice reduced joint stiffness and improved sleep quality. Gut comfort may improve, especially if pairing with a GLP-1 agonist. This is the initial assessment period: stay at the beginner dose.
Anti-inflammatory effects become noticeable. Reduced bloating and improved digestion. Minor soft tissue aches begin to resolve. Skin hydration starts to improve as GHK-Cu collagen pathways activate.
Peak healing response. Tendon and ligament repair accelerates. Skin elasticity visibly improves, particularly in areas affected by weight loss. Systemic inflammation markers (if tracked via bloodwork) may show measurable decline.
Full benefits reached. Skin firmness and tone at their best for the cycle. Gut lining integrity well-supported. Users on GLP-1 therapy often report fewer GI side effects by this point. Evaluate results and prepare for the off-cycle.
Four-week break. BPC-157 and TB-500 healing effects persist as tissue remodeling continues. Collagen benefits from GHK-Cu have a slow turnover and remain visible. Reassess before starting another cycle.
Week 1 to 2 (Tolerance Assessment). Component absorption kicks in quickly. GHK-Cu activates fibroblast signaling within hours of injection; BPC-157 and KPV reach tissue concentrations within days based on animal PK data. Community reports describe subtle energy improvements and reduced joint stiffness. Users on GLP-1 agonists may notice early gut comfort improvements. Most people won't see dramatic changes yet. This window is about confirming you tolerate the blend at beginner dose (2000mcg/day). Common side effects include injection site redness and itching (usually gone within an hour), copper skin flushing in sensitive individuals, and mild nausea if injecting on an empty stomach. Week 3 to 4 (Anti-Inflammatory Onset). KPV's NF-kB suppression starts producing measurable anti-inflammatory effects in animal IBD models by this point. GHK-Cu collagen gene upregulation continues building from week 1. Users report reduced bloating, improved digestion, and fading joint stiffness. Early skin hydration improvement shows up. The transient fatigue some people feel in week 1 generally resolves by now. Week 5 to 7 (Peak Healing Response). This is the window where GHK-Cu-mediated collagen and elastin synthesis hits its stride, based on gene expression timelines from Pickart's research. BPC-157 angiogenic and tendon outgrowth effects reach peak activity in animal models. Community feedback points to visible skin elasticity gains, especially in areas with rapid fat loss. Tendon and ligament soreness fades. GLP-1 users commonly report that GI side effects have dropped off considerably. Week 8 to 10 (Full Cycle Benefit). Tissue remodeling continues but you've hit the plateau. No human data exists for this time window specifically. Community reports indicate skin firmness and tone are at their best. Gut lining support appears well-established subjectively. This is the evaluation period before stepping into the off-cycle. Week 11 to 14 (Off-Cycle Retention). Collagen driven by GHK-Cu has slow biological turnover, so those benefits persist beyond the last dose. BPC-157 and TB-500 tissue remodeling continues for weeks post-cycle based on animal data. Most users report retaining their gains through the four-week break. Reassess results at the end of week 14 before deciding on the next cycle.
Component absorption begins. GHK-Cu activates fibroblast signaling within hours; BPC-157 and KPV reach relevant tissue concentrations within days (animal model PK data only).
Subtle energy improvement and reduced joint stiffness reported. GI comfort may improve in GLP-1 users. Most users report little change: this is the assessment window.
KPV NF-kB suppression reduces measurable inflammatory markers in IBD animal models by 2–3 weeks. GHK-Cu collagen gene upregulation is sustained from week 1.
Reduced bloating and improved digestion noted. Minor soft tissue aches and joint stiffness diminishing. Early skin hydration improvement reported.
Maximum GHK-Cu-mediated collagen and elastin synthesis (based on gene expression timelines in Pickart data). BPC-157 angiogenic and tendon outgrowth effects peak in this window in animal models.
Visible skin elasticity improvement, particularly in areas with rapid fat loss. Tendon/ligament soreness resolving. GLP-1 GI side effects reported as markedly reduced.
Tissue remodeling plateau continues; no human data for this time window.
Skin firmness and tone at best point in cycle. Gut lining appears well-supported subjectively. Users evaluate results before off-cycle.
GHK-Cu-driven collagen has slow biological turnover; benefits persist beyond last dose. BPC-157 and TB-500 tissue remodeling continues for weeks post-cycle (animal data).
Most gains reported as retained through off-cycle. Reassess at end of 4 weeks before deciding on next cycle.
Source: Weighted estimate across four components. BPC-157 has the shortest plasma half-life (~15 min per Sikiric et al.), followed by KPV (~1-2h), GHK-Cu (~2-4h), and TB-500 (~2-3h). The dominant component by mass is GHK-Cu (62.5% of the blend), which anchors the effective duration. No unified PK data exists for the combined four-peptide formulation.
Loading the interactive decay curve.
KLOW Blend components carry mixed regulatory status. BPC-157 and GHK-Cu were classified as FDA Category 2 bulk drug substances in 2023 to 2024. This restricts their use in compounding pharmacy preparations, though enforcement and interpretation vary. TB-500 and KPV remain unscheduled but are not FDA-approved for any indication. All four components are classified as research chemicals, not approved drugs. KLOW vials purchased from research vendors are sold for "research use only" and not for human consumption. Both BPC-157 and TB-500 are prohibited by WADA under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Any athlete subject to anti-doping testing must avoid this blend entirely. Compounding pharmacy availability for KLOW-type blends is legally uncertain given the Category 2 classifications. Research vendor sourcing remains the primary access route. This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before using any peptide product.
Peptide Schedule Research TeamReviewed Apr 202618 Citations
